ASHP Injectable Drug Information February 2025 Update

This update contains 4 new monographs, 96 revised monographs and 7 discontinued monographs.

New monographs: Antithymocyte Globulin (Equine); Crovalimab; Eculizumab; Ravulizumab.

Revised monographs: Acetylcysteine; Aldesleukin; Alprostadil; Amifostine; Amino Acids; Aminocaproic Acid; Amisulpride; Amivantamab; Amoxicillin SodiumClavulanate Potassium; Amphotericin B; Ampicillin Sodium; Ampicillin SodiumSulbactam Sodium; Anakinra; Antithymocyte Globulin (Rabbit); Appendix; Ascorbic Acid; AzaTHIOprine Sodium; Azithromycin; Bortezomib; Brexanolone; Bumetanide; Calcium Chloride; Calcium Gluconate; Ceftolozane SulfateTazobactam Sodium; Cisatracurium Besylate; Clarithromycin; Coagulation Factor Xa (Recombinant), Inactivated-zhzo; DAPTOmycin; Defibrotide Sodium; DexmedeTOMIDine Hydrochloride; Dexrazoxane Hydrochloride; Dextran 40; Diclofenac Sodium; DOCEtaxel; DroPERidol; Epoetin Alfa; Estrogens, Conjugated; Etomidate; Famotidine; Flumazenil; Fomepizole; Furosemide; Gentamicin Sulfate; Haloperidol Lactate; Heparin Sodium; HydrALAZINE Hydrochloride; HYDROmorphone Hydrochloride; Ibalizumab; Ibuprofen; Ibuprofen Lysinate; Indomethacin Sodium Trihydrate; Isosorbide Dinitrate; Ketamine Hydrochloride; Lacosamide; Letermovir; Leucovorin Calcium; Levocarnitine; Lipid Emulsion, Intravenous; LORazepam; Meloxicam; Meropenem; Mesna; Methylene Blue; MetroNIDAZOLE; Midazolam Hydrochloride; Milrinone Lactate; Mosunetuzumab; Multivitamins; Mycophenolate Mofetil Hydrochloride; Nafcillin Sodium; Ondansetron Hydrochloride; Papaverine Hydrochloride; Pentamidine Isethionate; Potassium Phosphates; Pyridoxine Hydrochloride; Remdesivir; Remifentanil Hydrochloride; Rocuronium Bromide; sildenafil citrate; Sodium Bicarbonate; Sodium Chloride; Sodium Phosphates; Sterile Water for Injection; Sugammadex Sodium; Tacrolimus; Tenoxicam; Teplizumab; Thiamine Hydrochloride; Tocilizumab; Ublituximab; Valproate Sodium; Vancomycin Hydrochloride; Vasopressin; Vinorelbine Tartrate; Vitamin A; Ziconotide Acetate.

Discontinued monographs: Bamlanivimab; Bebtelovimab; Casirivimab and Imdevimab; Cilgavimab; Etesevimab; Sotrovimab; Tixagevimab.